Offices of Howard G. Smith announces that it is investigating
potential claims on behalf of investors of CytRx Corporation ("CytRx" or
the "Company") (NASDAQ:CYTR) concerning possible violations of federal
securities laws. The investigation focuses on the Company's operations
and financial performance and prospects.
CytRx is a biopharmaceutical research and development company
specializing in oncology. The Company's oncology pipeline includes two
programs, aldoxorubicin and tamibarotene, which are in clinical
development for cancer indications. The investigation is related to an
article published March 13, 2014, on SeekingAlpha.com, alleging
that the Company hired a promoter - The DreamTeam Group - to tout CytRx
stock without disclosing that it was paid by the Company to promote the
stock. The article further alleges that the articles were written under
multiple aliases and coordinated with the release of news and data from
the Company to interpret and amplify the effect of the news.
If you purchased CytRx Corporation shares before March 13, 2014,
if you have information or would like to learn more about these claims,
or if you have any questions concerning this announcement or your rights
or interests with respect to these matters, please contact Howard G.
Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike,
Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847,
Toll Free at (888) 638-4847, or by email to email@example.com,
or visit our website at www.howardsmithlaw.com.
[ Back To NFVZone's Homepage ]